<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HEXALEN- altretamineÂ capsuleÂ </strong><br>MGI PHARMA, INC.<br></p></div>
<h1>HEXALEN<span class="Sup">Â®</span><br> (ALTRETAMINE) CAPSULES  50 mg</h1>
<div class="Contents">
<div class="Section">
<a name="dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-2"></a><p></p>
<p class="First">HEXUS PO5</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">MGI <br>PHARMA</span></p>
</div>
<div class="Warning">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>WARNINGS</h1>
<ol class="Arabic">
<li>HEXALEN<span class="Sup">Â®</span> capsules should only be given under the supervision of a physician experienced in the use of antineoplastic agents.</li>
<li>Peripheral blood counts should be monitored at least monthly, prior to the initiation of each course of HEXALEN<span class="Sup">Â®</span> capsules, and as clinically indicated (see <a href="#s19">Adverse Reactions</a>).</li>
<li>Because of the possibility of HEXALEN<span class="Sup">Â®</span> capsules-related <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, neurologic examination should be performed regularly during HEXALEN<span class="Sup">Â®</span> capsules administration (see <a href="#s19">Adverse Reactions</a>).</li>
</ol>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">HEXALEN<span class="Sup">Â®</span> (altretamine) capsules, is a synthetic cytotoxic antineoplastic s-triazine derivative. HEXALEN<span class="Sup">Â®</span> capsules contain 50 mg of altretamine for oral administration. Inert ingredients include lactose, anhydrous and calcium stearate. Altretamine, known chemically as <span class="Underline">N</span>,<span class="Underline">N</span>,<span class="Underline">N</span>',<span class="Underline">N</span>',<span class="Underline">N</span>â€?,<span class="Underline">N</span>â€?-hexamethyl-1,3,5-triazine-2,4,6-triamine, has the following structural formula:</p>
<div class="Figure">
<a name="f1"></a><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90a5e59a-bee8-404a-ad69-fabddeaf27f9&amp;name=hexalen-01.jpg">
</div>
<p>Its empirical formula is C9H18N6 with a molecular weight of 210.28. Altretamine is a white crystalline powder, melting at 172Â°Â± 1Â°C. Altretamine is practically insoluble in water but is increasingly soluble at pH 3 and below.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The precise mechanism by which HEXALEN<span class="Sup">Â®</span> capsules exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, HEXALEN<span class="Sup">Â®</span> capsules resembles the alkylating agent triethylenemelamine, yet <span class="Italics">in vitro</span> tests for alkylating activity of HEXALEN<span class="Sup">Â®</span>  capsules and its metabolites have been negative. HEXALEN<span class="Sup">Â®</span>  capsules has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement for cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span>, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.</p>
<p>HEXALEN<span class="Sup">Â®</span> capsules is well-absorbed following oral administration in humans, but undergoes rapid and extensive demethylation in the liver, producing variation in altretamine plasma levels. The principal metabolites are pentamethylmelamine and tetramethylmelamine.</p>
<p>Pharmacokinetic studies were performed in a limited number of patients and should be considered preliminary. After oral administration of HEXALEN<span class="Sup">Â®</span> capsules to 11 patients with advanced ovarian cancer in doses of 120-300 mg/m<span class="Sup">2</span>, peak plasma levels (as measured by gas-chromatographic assay) were reached between 0.5 and 3 hours, varying from 0.2 to 20.8 mg/l. Half-life of the Î²-phase of elimination ranged from 4.7 to 10.2 hours. Altretamine and metabolites show binding to plasma proteins. The free fractions of altretamine, pentamethylmelamine and tetramethylmelamine are 6%, 25% and 50%, respectively.</p>
<p>Following oral administration of <span class="Sup">14</span>C-ring-labeled altretamine (4 mg/kg), urinary recovery of radioactivity was 61% at 24 hours and 90% at 72 hours. Human urinary metabolites were Ndemethylated homologues of altretamine with &lt;1% unmetabolized altretamine excreted at 24 hours.</p>
<p>After intraperitoneal administration of <span class="Sup">14</span>C-ring-labeled altretamine to mice, tissue distribution was rapid in all organs, reaching a maximum at 30 minutes. The excretory organs (liver and kidney) and the small intestine showed high concentrations of radioactivity, whereas relatively low concentrations were found in other organs, including the brain.</p>
<p>There have been no formal pharmacokinetic studies in patients with compromised hepatic and/or renal function, though HEXALEN<span class="Sup">Â®</span> capsules has been administered both concurrently and following nephrotoxic drugs such as cisplatin.</p>
<p>HEXALEN<span class="Sup">Â®</span> capsules has been administered in 4 divided doses, with meals and at bedtime, though there is no pharmacokinetic data on this schedule nor information from formal interaction studies about the effect of food on its bioavailability or pharmacokinetics.</p>
<p>In two studies in patients with persistent or recurrent ovarian cancer following first-line treatment with cisplatin and/or alkylating agent-based combinations, HEXALEN<span class="Sup">Â®</span> capsules was administered as a single agent for 14 or 21 days of a 28 day cycle. In the 51 patients with measurable or evaluable disease, there were 6 clinical complete responses, 1 pathologic complete response, and 2 partial responses for an overall response rate of 18%. The duration of these responses ranged from 2 months in a patient with a palpable pelvic <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> to 36 months in a patient who achieved a pathologic complete response. In some patients, tumor regression was associated with improvement in symptoms and performance status.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS and USAGE</h1>
<p class="First">HEXALEN<span class="Sup">Â®</span> (altretamine) capsules is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">HEXALEN<span class="Sup">Â®</span> capsules is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it. HEXALEN<span class="Sup">Â®</span> capsules should not be employed in patients with preexisting severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> or severe neurologic toxicity. HEXALEN<span class="Sup">Â®</span> capsules has been administered safely, however, to patients heavily pretreated with cisplatin and/or alkylating agents, including patients with preexisting cisplatin neuropathies. Careful monitoring of neurologic function in these patients is essential.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s9"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <a href="#s4">boxed Warnings</a>.</p>
<p>Concurrent administration of HEXALEN<span class="Sup">Â®</span> capsules and antidepressants of the monoamine oxidase (MAO) inhibitor class may cause severe <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>. Four patients, all over 60 years of age, were reported to have experienced symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> after 4 to 7 days of concomitant therapy with HEXALEN<span class="Sup">Â®</span> capsules and MAO inhibitors.</p>
<p>HEXALEN<span class="Sup">Â®</span> capsules causes mild to moderate <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>. Blood counts and a neurologic examination should be performed prior to the initiation of each course of therapy and the dose of HEXALEN<span class="Sup">Â®</span> capsules adjusted as clinically indicated (see <a href="#s24">Dosage and Administration</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-7.1"></a><p></p>
<h2>Pregnancy: Category D</h2>
<p class="First">HEXALEN<span class="Sup">Â®</span> capsules has been shown to be embryotoxic and teratogenic in rats and rabbits when given at doses 2 and 10 times the human dose. HEXALEN<span class="Sup">Â®</span> capsules may cause fetal damage when administered to a pregnant woman. If HEXALEN<span class="Sup">Â®</span> capsules is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s11"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s12"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Neurologic examination should be performed regularly (see <a href="#s19">Adverse Reactions</a>).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s13"></a><a name="section-8.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Peripheral blood counts should be monitored at least monthly, prior to the initiation of each course of HEXALEN<span class="Sup">Â®</span> capsules, and as clinically indicated (see <a href="#s19">Adverse Reactions</a>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s14"></a><a name="section-8.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Concurrent administration of HEXALEN<span class="Sup">Â®</span> capsules and antidepressants of the MAO inhibitor class may cause severe <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (see <a href="#s9">Warnings</a> section). Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamine's half-life and toxicity in a rat model.</p>
<p>Data from a randomized trial of HEXALEN<span class="Sup">Â®</span> capsules and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>; however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN<span class="Sup">Â®</span> capsules and/or cisplatin (1).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s15"></a><a name="section-8.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">The carcinogenic potential of HEXALEN<span class="Sup">Â®</span> capsules has not been studied in animals, but drugs with similar mechanisms of action have been shown to be carcinogenic. HEXALEN<span class="Sup">Â®</span> capsules was weakly mutagenic when tested in <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100 of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span>. HEXALEN<span class="Sup">Â®</span> capsules administered to female rats 14 days prior to breeding through the gestation period had no adverse effect on fertility, but decreased post-natal survival at 120 mg/m<span class="Sup">2</span>/day and was embryocidal at 240 mg/m<span class="Sup">2</span>/day. Administration of 120 mg/m<span class="Sup">2</span>/day HEXALEN<span class="Sup">Â®</span> capsules to male rats for 60 days prior to mating resulted in <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, reduced fertility and a possible dominant lethal mutagenic effect. Male rats treated with HEXALEN<span class="Sup">Â®</span> capsules at 450 mg/m<span class="Sup">2</span>/day for 10 days had decreased spermatogenesis, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of testes, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> and ventral prostate.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s16"></a><a name="section-8.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Pregnancy Category D: see <a href="#s9">Warnings</a> section.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s17"></a><a name="section-8.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether altretamine is excreted in human milk. Because there is a possibility of toxicity in nursing infants secondary to HEXALEN<span class="Sup">Â®</span> capsules treatment of the mother, it is recommended that breast feeding be discontinued if the mother is treated with HEXALEN<span class="Sup">Â®</span> capsules.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s18"></a><a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of HEXALEN<span class="Sup">Â®</span> capsules in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s19"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-9.1"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">With continuous high-dose daily HEXALEN<span class="Sup">Â®</span> capsules, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of gradual onset occur frequently. Although in most instances these symptoms are controllable with anti-emetics, at times the severity requires HEXALEN<span class="Sup">Â®</span> capsules dose reduction or, rarely, discontinuation of HEXALEN<span class="Sup">Â®</span> capsules therapy. In some instances, a tolerance of these symptoms develops after several weeks of therapy. The incidence and severity of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are reduced with moderate-dose administration of HEXALEN<span class="Sup">Â®</span> capsules. In 2 clinical studies of single-agent HEXALEN<span class="Sup">Â®</span> capsules utilizing a moderate, intermittent dose and schedule, only 1 patient (1%) discontinued HEXALEN<span class="Sup">Â®</span> capsules due to severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> and central nervous system symptoms (mood disorders, disorders of consciousness, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>) have been reported. They are more likely to occur in patients receiving continuous high-dose daily HEXALEN<span class="Sup">Â®</span> (altretamine) capsules than moderate-dose HEXALEN<span class="Sup">Â®</span> capsules administered on an intermittent schedule. Neurologic toxicity has been reported to be reversible when therapy is discontinued. Data from a randomized trial of HEXALEN<span class="Sup">Â®</span> capsules and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>; however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN<span class="Sup">Â®</span> capsules and/or cisplatin (1).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-9.3"></a><p></p>
<h2>Hematologic</h2>
<p class="First">HEXALEN<span class="Sup">Â®</span> capsules causes mild to moderate dose-related <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> below 3000 WBC/mm<span class="Sup">3</span> occurred in &lt;15% of patients on a variety of intermittent or continuous dose regimens. Less than 1% had <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> below 1000 WBC/mm<span class="Sup">3</span>. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> below 50,000 platelets/mm<span class="Sup">3</span> was seen in &lt;10% of patients. When given in doses of 8-12 mg/kg/day over a 21 day course, nadirs of leukocyte and platelet counts were reached by 3-4 weeks, and normal counts were regained by 6 weeks. With continuous administration at doses of 6-8 mg/kg/day, nadirs are reached in 6-8 weeks (median).</p>
<p>Data in the following table are based on the experience of 76 patients with ovarian cancer previously treated with a cisplatin-based combination regimen who received single-agent HEXALEN<span class="Sup">Â®</span> capsules. In one study, HEXALEN<span class="Sup">Â®</span> capsules, 260 mg/m<span class="Sup">2</span>/day, was administered for 14 days of a 28 day cycle. In another study, HEXALEN<span class="Sup">Â®</span> capsules, 6-8 mg/kg/day, was administered for 21 days of a 28 day cycle.</p>
<table width="100%">
<caption><span>ADVERSE EXPERIENCES IN 76 PREVIOUSLY   TREATED OVARIAN CANCER PATIENTS   RECEIVING SINGLE-AGENT HEXALEN<span class="Sup">Â®</span>  CAPSULES</span></caption>
<tbody class="Headless"><tr class="First Last"><td>
<a name="f2"></a><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90a5e59a-bee8-404a-ad69-fabddeaf27f9&amp;name=hexalen-02.jpg">
</td></tr></tbody>
</table>
<p>Additional adverse reaction information is available from 13 single-agent altretamine studies (total of 1014 patients) conducted under the auspices of the National Cancer Institute. The treated patients had a variety of tumors and many were heavily pretreated with other chemotherapies; most of these trials utilized high, continuous daily doses of altretamine (612 mg/kg/day). In general, adverse reaction experiences were similar in the two trials described above. Additional toxicities, not reported in the above table, included hepatic toxicity, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, each occurring in &lt;1% of patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s23"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No case of acute overdosage in humans has been described. The oral LD50 dose in rats was 1050 mg/kg and 437 mg/kg in mice.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s24"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">HEXALEN<span class="Sup">Â®</span> capsules is administered orally. Doses are calculated on the basis of body surface area.</p>
<p>HEXALEN<span class="Sup">Â®</span> capsules may be administered either for 14 or 21 consecutive days in a 28 day cycle at a dose of 260 mg/m<span class="Sup">2</span>/day. The total daily dose should be given as 4 divided oral doses after meals and at bedtime. There is no pharmacokinetic information supporting this dosing regimen and the effect of food on HEXALEN<span class="Sup">Â®</span> capsules bioavailability or pharmacokinetics has not been evaluated.</p>
<p>HEXALEN<span class="Sup">Â®</span> capsules should be temporarily discontinued (for 14 days or longer) and subsequently restarted at 200 mg/m<span class="Sup">2</span>/day for any of the following situations:</p>
<ol class="Arabic">
<li>Gastrointestinal intolerance unresponsive to symptomatic measures;</li>
<li>White blood count &lt;2000/mm<span class="Sup">3</span> or granulocyte count &lt;1000/mm<span class="Sup">3</span>;</li>
<li>Platelet count &lt;75,000/mm<span class="Sup">3</span>;</li>
<li>Progressive <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.</li>
</ol>
<p>If <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> fail to stabilize on the reduced dose schedule, HEXALEN<span class="Sup">Â®</span> capsules should be discontinued indefinitely.</p>
<p>Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published (2-9). There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s25"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">HEXALEN<span class="Sup">Â®</span> (altretamine) capsules is available in 50 mg clear, hard gelatin capsules imprinted with the following inscription:</p>
<dl>
<dt>Â </dt>
<dd>USB 001.</dd>
<dt>Â </dt>
<dd>Bottles of 100 capsules</dd>
<dt>Â </dt>
<dd>(NDC 58063-001-70)</dd>
</dl>
<p>Store up to 25ÂºC (77ÂºF); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F).</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s26"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Wiernik PH, et al. Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group. <span class="Italics">Cancer Invest.</span> 1992; 10(1): 1-9.</li>
<li>ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, Pa: Oncology Nursing Society; 1999:32-41.</li>
<li>U.S. Department of Health and Human Services. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. Washington DC: Division of Safety, National Institutes of Health; 1983 Public Health Service publication NIH 83-2621.</li>
<li>AMA Council on Scientific Affairs. Guidelines for Handling Parenteral Antineoplastics. <span class="Italics">JAMA.</span> 1985; 253:1590-1591.</li>
<li>National Study Commission on Cytotoxic Exposure. Recommendations for Handling Cytotoxic Agents. Boston, MA: Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115; 1987.</li>
<li>Clinical Oncological Society of Australia: Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. <span class="Italics">Med J Australia</span>. 1983;1:426-428.</li>
<li>Jones RB, Frank R, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> T. Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. C<span class="Italics">A Cancer J Clin.</span> 1983;33:258-263.</li>
<li>American Society of Hospital Pharmacists. ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. <span class="Italics">Am J of Hosp Pharm</span>. 1990; 47:1033-1049.</li>
<li>OSHA Work Practice Guidelines. Controlling Occupational Exposure to Hazardous Drugs. <span class="Italics">Am J Health Syst Pharm</span>. 1996;53:1669-1685.</li>
</ol>
<p class="First">HEXALEN<span class="Sup">Â®</span> (altretamine) capsules is a registered trademark of MGI PHARMA, INC.</p>
<p>Manufactured by:  <br><span class="Bold">AAI Development Services</span></p>
<p>An aaiPharma<span class="Sup">Â®</span> Company <br>1726 North 23<span class="Sup">rd</span> St. <br>Wilmington, <br>North Carolina  28405 <br></p>
<p>Manufactured for:  <br></p>
<p><span class="Bold">MGI PHARMA, INC.</span><br>Bloomington,  Minnesota  <br>55437</p>
<p>For Medical Inquiries call: 1-800-562-5580</p>
<p>Revision Date November, 2003  HEXUS PO5</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HEXALENÂ 		
					</strong><br><span class="contentTableReg">altretamine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58063-001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>altretamine</strong> (altretamine) </td>
<td class="formItem"></td>
<td class="formItem">50Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Anhydrous lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Calcium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Capsugel size 3 hard gelatin capsule</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (NATURAL) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">3mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">USB;001</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58063-001-70</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>MGI PHARMA, INC.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>90a5e59a-bee8-404a-ad69-fabddeaf27f9</div>
<div>Set id: 90a5e59a-bee8-404a-ad69-fabddeaf27f9</div>
<div>Version: 1</div>
<div>Effective Time: 20061231</div>
</div>
</div>Â <div class="DistributorName">MGI PHARMA, INC.</div></p>
</body></html>
